Last week, a group focused on the harms of fentanyl filed a Section 301 petition with the Office of the United States Trade Representative (USTR), arguing that China's "acts, policies, and practices" in this area harm U.S. commerce, and requesting a range of tariffs and other remedies as a response.
You don't have access to this post on China Trade Monitor at the moment, but if you upgrade your account you'll be able to see the whole thing, as well as all the other posts in the archive! Subscribing only takes a few seconds and will give you immediate access.
This post is for subscribers only
Subscribe now
Already have an account? Sign in
